X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
The net proceeds will be used for the commmercilization in the U.S. of Xdemy (lotilaner), which is designed to target and kill the Demodex mites that cause eyelid redness and crusties (collarettes) due to Demodex blepharitis.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: Xdemvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 29, 2024
Details:
TP-05 (lotilaner) is an oral, well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. It is being evaluated for the prevention of Lyme Disease.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Product Name: TP-05
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel small molecule, approved for Demodex blepharitis under the brand name Xdemvy. Now it is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis via targeting and eradicating the root cause by selectively inhibiting the GABA-Cl channels.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
The company intends to use the net proceeds to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: Xdemvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 01, 2023
Details:
The company intends to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease, or MGD, TP-04 and TP-05.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: Xdemvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 31, 2023
Details:
Xdemvy (lotilaner ophthalmic solution), a novel prescription eye drop, is recently approved by FDA and is designed to treat demodex blepharitis by targeting and eradicating the root cause of the disease, demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: Xdemvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tarsus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks that transmit Lyme disease by selectively inhibiting parasite-specific GABA-CI channels.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Product Name: TP-05
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
TP-03 (lotilaner) met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
TP-03, is a topical ophthalmic formulation of lotilaner designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease–Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.
Lead Product(s): Lotilaner
Therapeutic Area: Infections and Infectious Diseases Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
The new Saturn-1 data reinforce the strong potential clinical utility of TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis, with a broad range of patients showing a substantial response.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2021
Details:
Tarsus has completed four Phase 2 clinical trials of TP-03 in Demodex blepharitis, all of which fulfilled their endpoints with no serious side events or treatment discontinuation.
Lead Product(s): Lotilaner
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
